Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas

Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 1999-08, Vol.74 (2), p.202-207
Hauptverfasser: Anderson, P.S., Smith, H.O., Jones, J.G., Goldberg, G.L., Fields, A.L., Runowicz, C.D., Pollard, J.W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 207
container_issue 2
container_start_page 202
container_title Gynecologic oncology
container_volume 74
creator Anderson, P.S.
Smith, H.O.
Jones, J.G.
Goldberg, G.L.
Fields, A.L.
Runowicz, C.D.
Pollard, J.W.
description Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25–50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25–50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.
doi_str_mv 10.1006/gyno.1999.5446
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69915716</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009082589995446X</els_id><sourcerecordid>69915716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-8d9fe2e446e84017b7129d96ea06aa619d0e578996f417c0bfecd532270e54443</originalsourceid><addsrcrecordid>eNp1kE1r3DAQhkVJaLZJrz0GHUJv3oxsWfYcw7ZpAqEJ-TgLrTzeKNjSRtIG9t_Xyy60l54GXp55mXkY-yZgLgDU5Wrrw1wg4ryWUn1iMwFYF6qt8YjNABCKtqzbE_YlpTcAqECUn9mJACmwqcoZWy3CEPy2eMpu3AwmO7_i18bmEAvBje_4bU78kSytp4j_CPx3yPzGfBA3_DEMxJ3n-ZX4g8mvYUWekks89PwlU3Se-JOJNowmnbHj3gyJvh7mKXu5_vm8uCnu7n_dLq7uClspzEXbYU8lTa9QK0E0y0aU2KEiA8oYJbADqpsWUfVSNBaWPdmursqymXIpZXXKvu971zG8byhlPbpkaRiMp7BJWiGKuhFqAud70MaQUqRer6MbTdxqAXqnVu_U6p1avVM7LZwfmjfLkbp_8L3LCbg4ACZZM_TReOvSXw6FRAET1u4xmjR8OIo6WUfeUuci2ay74P53wh_wWZP5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69915716</pqid></control><display><type>article</type><title>Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Anderson, P.S. ; Smith, H.O. ; Jones, J.G. ; Goldberg, G.L. ; Fields, A.L. ; Runowicz, C.D. ; Pollard, J.W.</creator><creatorcontrib>Anderson, P.S. ; Smith, H.O. ; Jones, J.G. ; Goldberg, G.L. ; Fields, A.L. ; Runowicz, C.D. ; Pollard, J.W.</creatorcontrib><description>Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25–50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25–50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1999.5446</identifier><identifier>PMID: 10419732</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Biological and medical sciences ; colony-stimulating factor-1 (CSF-1) ; CSF-1 receptor (c-fms) ; Female ; Female genital diseases ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; Humans ; Macrophage Colony-Stimulating Factor - analysis ; Macrophage Colony-Stimulating Factor - biosynthesis ; Macrophage Colony-Stimulating Factor - physiology ; Medical sciences ; Receptor, Macrophage Colony-Stimulating Factor - analysis ; Receptor, Macrophage Colony-Stimulating Factor - biosynthesis ; Receptor, Macrophage Colony-Stimulating Factor - physiology ; Sarcoma - chemistry ; Sarcoma - etiology ; Tumors ; Uterine Neoplasms - chemistry ; Uterine Neoplasms - etiology ; uterine sarcomas</subject><ispartof>Gynecologic oncology, 1999-08, Vol.74 (2), p.202-207</ispartof><rights>1999 Academic Press</rights><rights>1999 INIST-CNRS</rights><rights>Copyright 1999 Academic Press.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-8d9fe2e446e84017b7129d96ea06aa619d0e578996f417c0bfecd532270e54443</citedby><cites>FETCH-LOGICAL-c369t-8d9fe2e446e84017b7129d96ea06aa619d0e578996f417c0bfecd532270e54443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1006/gyno.1999.5446$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1914910$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10419732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, P.S.</creatorcontrib><creatorcontrib>Smith, H.O.</creatorcontrib><creatorcontrib>Jones, J.G.</creatorcontrib><creatorcontrib>Goldberg, G.L.</creatorcontrib><creatorcontrib>Fields, A.L.</creatorcontrib><creatorcontrib>Runowicz, C.D.</creatorcontrib><creatorcontrib>Pollard, J.W.</creatorcontrib><title>Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25–50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25–50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.</description><subject>Biological and medical sciences</subject><subject>colony-stimulating factor-1 (CSF-1)</subject><subject>CSF-1 receptor (c-fms)</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Macrophage Colony-Stimulating Factor - analysis</subject><subject>Macrophage Colony-Stimulating Factor - biosynthesis</subject><subject>Macrophage Colony-Stimulating Factor - physiology</subject><subject>Medical sciences</subject><subject>Receptor, Macrophage Colony-Stimulating Factor - analysis</subject><subject>Receptor, Macrophage Colony-Stimulating Factor - biosynthesis</subject><subject>Receptor, Macrophage Colony-Stimulating Factor - physiology</subject><subject>Sarcoma - chemistry</subject><subject>Sarcoma - etiology</subject><subject>Tumors</subject><subject>Uterine Neoplasms - chemistry</subject><subject>Uterine Neoplasms - etiology</subject><subject>uterine sarcomas</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1r3DAQhkVJaLZJrz0GHUJv3oxsWfYcw7ZpAqEJ-TgLrTzeKNjSRtIG9t_Xyy60l54GXp55mXkY-yZgLgDU5Wrrw1wg4ryWUn1iMwFYF6qt8YjNABCKtqzbE_YlpTcAqECUn9mJACmwqcoZWy3CEPy2eMpu3AwmO7_i18bmEAvBje_4bU78kSytp4j_CPx3yPzGfBA3_DEMxJ3n-ZX4g8mvYUWekks89PwlU3Se-JOJNowmnbHj3gyJvh7mKXu5_vm8uCnu7n_dLq7uClspzEXbYU8lTa9QK0E0y0aU2KEiA8oYJbADqpsWUfVSNBaWPdmursqymXIpZXXKvu971zG8byhlPbpkaRiMp7BJWiGKuhFqAud70MaQUqRer6MbTdxqAXqnVu_U6p1avVM7LZwfmjfLkbp_8L3LCbg4ACZZM_TReOvSXw6FRAET1u4xmjR8OIo6WUfeUuci2ay74P53wh_wWZP5</recordid><startdate>19990801</startdate><enddate>19990801</enddate><creator>Anderson, P.S.</creator><creator>Smith, H.O.</creator><creator>Jones, J.G.</creator><creator>Goldberg, G.L.</creator><creator>Fields, A.L.</creator><creator>Runowicz, C.D.</creator><creator>Pollard, J.W.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990801</creationdate><title>Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas</title><author>Anderson, P.S. ; Smith, H.O. ; Jones, J.G. ; Goldberg, G.L. ; Fields, A.L. ; Runowicz, C.D. ; Pollard, J.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-8d9fe2e446e84017b7129d96ea06aa619d0e578996f417c0bfecd532270e54443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biological and medical sciences</topic><topic>colony-stimulating factor-1 (CSF-1)</topic><topic>CSF-1 receptor (c-fms)</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Macrophage Colony-Stimulating Factor - analysis</topic><topic>Macrophage Colony-Stimulating Factor - biosynthesis</topic><topic>Macrophage Colony-Stimulating Factor - physiology</topic><topic>Medical sciences</topic><topic>Receptor, Macrophage Colony-Stimulating Factor - analysis</topic><topic>Receptor, Macrophage Colony-Stimulating Factor - biosynthesis</topic><topic>Receptor, Macrophage Colony-Stimulating Factor - physiology</topic><topic>Sarcoma - chemistry</topic><topic>Sarcoma - etiology</topic><topic>Tumors</topic><topic>Uterine Neoplasms - chemistry</topic><topic>Uterine Neoplasms - etiology</topic><topic>uterine sarcomas</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, P.S.</creatorcontrib><creatorcontrib>Smith, H.O.</creatorcontrib><creatorcontrib>Jones, J.G.</creatorcontrib><creatorcontrib>Goldberg, G.L.</creatorcontrib><creatorcontrib>Fields, A.L.</creatorcontrib><creatorcontrib>Runowicz, C.D.</creatorcontrib><creatorcontrib>Pollard, J.W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, P.S.</au><au>Smith, H.O.</au><au>Jones, J.G.</au><au>Goldberg, G.L.</au><au>Fields, A.L.</au><au>Runowicz, C.D.</au><au>Pollard, J.W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1999-08-01</date><risdate>1999</risdate><volume>74</volume><issue>2</issue><spage>202</spage><epage>207</epage><pages>202-207</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25–50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25–50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>10419732</pmid><doi>10.1006/gyno.1999.5446</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 1999-08, Vol.74 (2), p.202-207
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_69915716
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Biological and medical sciences
colony-stimulating factor-1 (CSF-1)
CSF-1 receptor (c-fms)
Female
Female genital diseases
Gene Expression Regulation, Neoplastic
Gynecology. Andrology. Obstetrics
Humans
Macrophage Colony-Stimulating Factor - analysis
Macrophage Colony-Stimulating Factor - biosynthesis
Macrophage Colony-Stimulating Factor - physiology
Medical sciences
Receptor, Macrophage Colony-Stimulating Factor - analysis
Receptor, Macrophage Colony-Stimulating Factor - biosynthesis
Receptor, Macrophage Colony-Stimulating Factor - physiology
Sarcoma - chemistry
Sarcoma - etiology
Tumors
Uterine Neoplasms - chemistry
Uterine Neoplasms - etiology
uterine sarcomas
title Colony-Stimulating Factor-1 and Its Receptor Do Not Have a Role in the Pathogenesis of Uterine Sarcomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A21%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Colony-Stimulating%20Factor-1%20and%20Its%20Receptor%20Do%20Not%20Have%20a%20Role%20in%20the%20Pathogenesis%20of%20Uterine%20Sarcomas&rft.jtitle=Gynecologic%20oncology&rft.au=Anderson,%20P.S.&rft.date=1999-08-01&rft.volume=74&rft.issue=2&rft.spage=202&rft.epage=207&rft.pages=202-207&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1999.5446&rft_dat=%3Cproquest_cross%3E69915716%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69915716&rft_id=info:pmid/10419732&rft_els_id=S009082589995446X&rfr_iscdi=true